Streetbeat News

JYNT

The Joint Corp.

https://www.thejoint.com

Industry

Medical - Care Facilities

The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics. The company operates in two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising, and regional developers. As of March 1, 2022, the company operated approximately 700 locations in the United States. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.

Open

11.73

Mkt cap

174M

Volume

85K

High

11.75

P/E Ratio

-11.85

52-wk high

17.82

Low

11.05

Div yield

N/A

52-wk low

7.68

CEOs of Gauzy and Research Frontiers discuss their partnership and Ferrari's use of SPD technology in a Benzinga interview.

Portfolio Pulse from

November 06, 2024 | 9:15 pm

Wolf Haldenstein Adler Freeman & Herz LLP is investigating Joint Stock Company Kaspi.kz AO for potential violations of federal securities laws, focusing on the company's American Depositary Shares (NASDAQ: KSPI).

Portfolio Pulse from

November 05, 2024 | 12:30 pm

The Joint Corp has appointed Sanjiv Razdan as its new President and CEO, effective immediately, following the resignation of Peter Holt.

Portfolio Pulse from Benzinga Newsdesk

October 14, 2024 | 8:18 pm

The Joint Corp has reiterated its FY24 guidance, expecting system-wide sales to be between $530M and $545M. System-wide comp sales for clinics open 13 months or more are projected to be in the mid-single digits. The company plans to open 60 to 75 new franchised clinics in 2024, down from 104 in 2023.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 10:00 pm

Joint (NASDAQ:JYNT) reported Q2 2024 adjusted EPS of $(0.06), missing the $(0.02) estimate by 200%. However, sales of $30.261M beat the $29.397M estimate by 2.94%, showing a 3.26% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:52 pm

B. Riley Securities analyst Jeff Van Sinderen has maintained a Buy rating on Joint (NASDAQ:JYNT) and increased the price target from $12 to $20.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 5:37 pm

Joint Corp's shares surged following the announcement of their Q1 financial results, which exceeded expectations. Additionally, the company confirmed its full-year 2023 system-wide sales guidance. Roth MKM maintained a Buy rating on Joint Corp and increased the price target from $13 to $16.

Portfolio Pulse from Benzinga Newsdesk

May 03, 2024 | 3:57 pm

Roth MKM analyst George Kelly has reiterated a Buy rating on Joint (NASDAQ:JYNT) and increased the price target from $13 to $16.

Portfolio Pulse from Benzinga Newsdesk

May 03, 2024 | 2:36 pm

The Joint Corp. has reiterated its guidance for 2024, with system-wide sales expected to range between $530 million and $545 million.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 9:43 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.